Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan

References

• YamanakaHSugiyamaNInoueETaniguchiAMomoharaSEstimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I)Mod Rheumatol2014241334024261756
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnn Rheum Dis201069696497520444750
   PubMed Web of Science ®Google Scholar
• CurtisJRSinghJAThe use of biologics in rheumatoid arthritis: current and emerging paradigms of careClin Ther200133667970721704234
   PubMed Web of Science ®Google Scholar
• ListingJKekowJMangerBMortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximabAnn Rheum Dis201574241542124291654
   PubMed Web of Science ®Google Scholar
• CramerJRoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
   PubMed Web of Science ®Google Scholar
• BlumMAKooDDoshiJAMeasurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic reviewClin Ther201133790191321715007
   PubMed Web of Science ®Google Scholar
• LyuRGovoniMDingQTreatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in GermanyRheumatol Int201636114315326314368
   PubMed Web of Science ®Google Scholar
• ZinkAListingJKarySTreatment continuation in patients receiving biological agents or conventional DMARD therapyAnn Rheum Dis20056491274127915708884
   PubMed Web of Science ®Google Scholar
• NeubauerSCifaldiMMittendorfTGanguliAWolffMZeidlerJBiologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in GermanyHealth Econ Rev2014413226208932
   PubMedGoogle Scholar
• CarmonaLGomez-ReinoJJBIOBADASER GroupSurvival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASERArthritis Res Ther200683R7216620398
   PubMed Web of Science ®Google Scholar
• KievitWFransenJAdangEMLong-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch rheumatoid arthritis monitoring registerRheumatology201150119620321078625
   PubMed Web of Science ®Google Scholar
• MarkatseliTEAlamanosYSaougouIVoulgariPVDrososAASurvival of TNF-alpha antagonists in rheumatoid arthritis: a long-term studyClin Exp Rheumatol2012301313822153557
   PubMed Web of Science ®Google Scholar
• JobanputraPMaggsFDeemingAA randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 yearsBMJ Open201226e001395
   Web of Science ®Google Scholar
• SvedbornADalenJLyuRTreatment persistence among patients with rheumatoid disease (RD) newly treated with subcutaneous TNF alpha blockersAnn Rheum Dis201574330
   Web of Science ®Google Scholar
• SangiorgiDBenucciMNappiCPerroneVBudaSDegli EspostiLDrug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritisBiologics2015911912726604680
   PubMedGoogle Scholar
• Du PanSMDehlerSCiureaAZiswilerHRGabayCFinckhASwiss Clinical Quality Management PhysiciansComparison of drug retention rates and causes of drug discontinuation between anti–tumor necrosis factor agents in rheumatoid arthritisArthritis Rheum200961556056819405000
   PubMed Web of Science ®Google Scholar
• FisherABassettKWrightJMBrookhartMAFreemanHDormuthCRComparative persistence of the TNF antagonists in rheumatoid arthritis – a population-based cohort studyPLoS One201498e10519325141123
   PubMed Web of Science ®Google Scholar
• JohnstonSMcMorrowDFarrAJuneauPOgaleSComparison of biologic disease-modifying antirheumatic drug therapy persistence between biologics among rheumatoid arthritis patients switching from another biologicRheum Ther2015215971
   PubMed Web of Science ®Google Scholar
• TangBRahmanMWatersHCCallegariPTreatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritisClin Ther20083071375138418691998
   PubMed Web of Science ®Google Scholar
• BorahBHuangXZarotskyVGlobeDTrends in RA patients’ adherence to subcutaneous anti-TNF therapies and costsCurr Med Res Opin20092561365137719425902
   PubMed Web of Science ®Google Scholar
• AgarwalSGlassRShadickNPredictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritisJ Rheumatol20083591737174418634159
   PubMed Web of Science ®Google Scholar
• RamiroSLandewéRvan der HeijdeDHarrisonDCollierDMichaudKDiscontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non TNF inhibitors?RMD Open201511e00015526629366
   PubMedGoogle Scholar
• BaserOGanguliARoySXieLCifaldiMImpact of switching from an initial tumor necrosis factor inhibitor on health care resource utilization and costs among patients with rheumatoid arthritisClin Ther20153771454146525999184
   PubMed Web of Science ®Google Scholar
• ChoSKSungYKChoiCBBaeSCImpact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean national health insurance claims dataRheumatol Int201232123851385622193228
   PubMed Web of Science ®Google Scholar
• KangJHParkDJLeeJWDrug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitisJ Korean Med Sci20142991205121125246737
   PubMed Web of Science ®Google Scholar
• SakaiRTanakaMNankiTDrug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target moleculesAnn Rheum Dis201271111820182622504558
   PubMed Web of Science ®Google Scholar
• SaokaewSSugimotoTKamaeIPratoomsootCChaiyakunaprukNHealthcare databases in Thailand and Japan: potential sources for health technology assessment researchPLoS One20151011e014199326560127
   PubMed Web of Science ®Google Scholar
• WangKLiPChenLKatoKKobayashiMYamauchiKImpact of the Japanese diagnosis procedure combination-based payment system in JapanJ Med Syst20103419510020192060
   PubMed Web of Science ®Google Scholar
• QuanHSundararajanVHalfonPCoding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative dataMed Care200543111130113916224307
   PubMed Web of Science ®Google Scholar
• WuEChenLBirnbaumHYangECifaldiMRetrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritisCurr Med Res Opin20082482229224018577308
   PubMed Web of Science ®Google Scholar
• YeawJBennerJSWaltJGSianSSmithDBComparing adherence and persistence across 6 chronic medication classesJ Manag Care Pharm200915972874019954264
   PubMed Web of Science ®Google Scholar
• SinghJASaagKGBridgesSLJr2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritisArthritis Rheumatol201668112626545940
   PubMed Web of Science ®Google Scholar
• LeePWaltJChiangTGuckianAKeenerJA gap analysis approach to assess patient persistence with glaucoma medicationAm J Ophthalmol2007144452052417692273
   PubMed Web of Science ®Google Scholar
• OgaleSHitrayaEHenkHPatterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort studyBMC Musculoskelet Disord20111220421929807
   PubMed Web of Science ®Google Scholar
• TanakaYTakeuchiTInoueERetrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)Mod Rheumatol200818214615218283523
   PubMed Web of Science ®Google Scholar
• KoikeTHarigaiMInokumaSPostmarketing surveillance of the safety and effectiveness of etanercept in JapanJ Rheumatol200936589890619332630
   PubMed Web of Science ®Google Scholar
• FewtrellMKennedyKSinghalAHow much loss to follow-up is acceptable in long-term randomised trials and prospective studies?Arch Dis Child20089345846118495909
   PubMed Web of Science ®Google Scholar
• PetriHUrquhartJChanneling bias in the interpretation of drug effectsStat Med19911045775812057656
   PubMed Web of Science ®Google Scholar
• ChiaLRSchlenkEADunbar-JacobJEffect of personal and cultural beliefs on medication adherence in the elderlyDrugs Aging200623319120216608375
   PubMed Web of Science ®Google Scholar
• MatsubaraHKojimaTKanekoALong-term retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapyJ Rheumatol20144181583158925028370
   PubMed Web of Science ®Google Scholar
• SalaffiFCarottiMDi CarloMFarahSGutierrezMAdherence to anti-tumor necrosis factor therapy administered subcutaneously and associated factors in patients with rheumatoid arthritisJ Clin Rheumatol201521841942526587852
   PubMed Web of Science ®Google Scholar
• BarbosaCDBalpMMKulichKGermainNRofailDA literature review to explore the link between treatment satisfaction and adherence, compliance, and persistencePatient Prefer Adherence20126394822272068
   PubMed Web of Science ®Google Scholar
• MorganCMcBethJCordingleyLThe influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics eraRheumatology (Oxford)201554101780179125972390
   PubMed Web of Science ®Google Scholar